Invivyd, Inc. (IVVD)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Robert D. Allen Ph.D. | Chief Scientific Officer | 828.18k | -- | 1969 |
| Ms. Jill Andersen J.D. | Chief Legal Officer & Corporate Secretary | 931.68k | -- | 1973 |
| Mr. Jeremy Gowler | Interim CEO, COO & Chief Commercial Officer | -- | -- | 1977 |
| Mr. William E. Duke Jr., M.B.A. | Chief Financial Officer | -- | -- | 1972 |
| Ms. Stacy Price M.S. | Chief Technology & Manufacturing Officer | -- | -- | 1969 |
| Scott Young | Senior Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Ms. Julie Green M.B.A. | Chief Human Resources Officer | -- | -- | 1975 |
| Ms. Heidi Spurling M.S. | VP of Strategy & Operations and Chief of Staff to the CEO | -- | -- | -- |
Invivyd, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 94
Description
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. It developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. The company's pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Recent Events
- Apr 18, 2024DEF 14A: Proxy StatementsSee Full Filing
- Apr 12, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 04, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 28, 202410-K: Periodic Financial ReportsSee Full Filing
- Mar 25, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Upcoming Events Information Not Available